Related Experiment Video
Updated: Jun 26, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Small Molecule Functional Converter of B-Cell Lymphoma-2 (Bcl-2) Suppresses Breast Cancer Lung Metastasis
Prasad R Kopparapu1, Christiane V Löhr2, Martin C Pearce1
1Cancer Research Laboratory, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon 97331-8580, United States.
Abstract:
The B-cell lymphoma-2 (Bcl-2) family of proteins plays a vital role in tumorigenesis. Cancer cells utilize the expression of Bcl-2 to evade therapy and develop resistance. Bcl-2 overexpression also causes cancer cells to be more invasive and metastatic. About 80% of cancer deaths are due to metastases, and yet targeted therapies for metastatic cancers are scarce. We discovered a small molecule, BFC1103, which changes the conformation of Bcl-2 to convert the antiapoptotic protein to a proapoptotic protein. BFC1103-induced apoptosis is dependent on the expression levels of Bcl-2, with higher levels causing more apoptosis. BFC1103 suppressed the growth of breast cancer lung metastasis. BFC1103 has the potential for further optimization and development for clinical testing in metastatic cancers that express Bcl-2. This study demonstrates a new approach to target Bcl-2 using a small molecule, BFC1103, to suppress metastatic disease.
Insights
A novel small molecule, BFC1103, targets B-cell lymphoma-2 (Bcl-2) by converting it to a proapoptotic protein. This approach effectively suppresses breast cancer metastasis and offers potential for treating Bcl-2-expressing metastatic cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The B-cell lymphoma-2 (Bcl-2) protein family is crucial in cancer development, promoting cell survival and resistance to therapy.
- Overexpression of Bcl-2 contributes to cancer cell invasiveness and metastasis, a primary cause of cancer-related mortality.
- Targeted therapies for metastatic cancers remain limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To discover and characterize a small molecule that targets Bcl-2.
- To investigate the potential of this molecule in suppressing cancer metastasis.
- To establish a new therapeutic approach for Bcl-2-expressing metastatic cancers.
Main Methods:
- Discovery of a small molecule, BFC1103, designed to alter Bcl-2 conformation.
- Assessment of BFC1103's ability to induce apoptosis in cancer cells.
- Evaluation of BFC1103's efficacy in suppressing breast cancer lung metastasis in preclinical models.
Main Results:
- BFC1103 was found to convert the antiapoptotic Bcl-2 protein into a proapoptotic one.
- The molecule's apoptotic effect was directly correlated with Bcl-2 expression levels.
- BFC1103 demonstrated significant suppression of breast cancer lung metastasis growth.
Conclusions:
- BFC1103 represents a novel therapeutic strategy targeting Bcl-2.
- The molecule shows promise for clinical development in treating metastatic cancers that overexpress Bcl-2.
- This study introduces a new method for targeting Bcl-2 to combat metastatic disease.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...